| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments for offering costs in connection with at-the-market offering and initial public offering | 0 | - |
| Net cash provided by financing activities | 18,321 | 18,457 |
| Net change in cash and cash equivalents and restricted cash | -14,290 | -18,838 |
| Cash and cash equivalents at beginning of period | 143,361 | - |
| Cash and cash equivalents at end of period | 129,071 | - |
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)